Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies: The ESNV-SPA Study Protocol

Éric Azabou, Guillaume Bao, Félicie Costantino, Madalina Jacota, Chanez Lazizi, Lionelle Nkam, Martin Rottman, Anne‐Laure Roux, Sylvain Chevallier, Lamiae Grimaldi, Maxime BrébanFrontiers in Human Neuroscience 2021 · DOI

Abstract

Axial spondyloarthritis (SpA) is a chronic inflammatory condition causing significant pain and disability. With nearly 50% of patients developing resistance to standard biological therapies, there is a critical need for alternative treatments. This protocol describes the ESNV-SPA study, a double-blind, randomized cross-over clinical trial evaluating non-invasive vagus nerve stimulation (nVNS). By targeting the cholinergic anti-inflammatory reflex, nVNS aims to reduce pro-inflammatory cytokines. The study will involve 120 drug-resistant SpA patients, comparing 12 weeks of active taVNS against dummy stimulation, with a primary endpoint of ASAS20 response.

Introduction: Addressing Drug Resistance in Axial SpA

Axial spondyloarthritis (SpA) primarily affects the spine and sacroiliac joints. While biological therapies (biologics) targeting TNFα and IL-17 have significantly improved outcomes, a substantial portion of the patient population remains underserved due to primary non-response, secondary loss of efficacy, or adverse effects.

The ESNV-SPA study explores bioelectronic medicine as a solution. The central hypothesis rests on the "cholinergic anti-inflammatory pathway" (CAP). In this regulatory circuit, the vagus nerve communicates with the immune system to inhibit the production of pro-inflammatory cytokines like TNFα, IL-1β, and IL-6. By stimulating the vagus nerve non-invasively, researchers hope to "hack" this natural reflex to manage systemic inflammation without the risks associated with long-term pharmacological immunosuppression.

Methods and Study Design

The ESNV-SPA trial is designed as a multicenter, double-blind, randomized 2x2 cross-over study.

The Intervention

The study utilizes a transcutaneous auricular vagus nerve stimulator (taVNS), specifically the Tens Eco Plus.

  • Active Stimulation: Applied to the cymba conchae of the left ear, a region densely innervated by the auricular branch of the vagus nerve.
  • Dummy Stimulation: Applied to the left ear lobule, which lacks significant vagal innervation and serves as an anatomical control.
  • Dosing: Patients receive one hour of stimulation once per week at an intensity of 2–5 mA.

Cross-Over Protocol

To maximize statistical power and allow each patient to serve as their own control, the study employs a cross-over design. Patients are randomized into two sequences:

  1. Group A: 12 weeks of active VNS, followed by a 4-week washout period, then 12 weeks of dummy stimulation.
  2. Group B: 12 weeks of dummy stimulation, followed by a 4-week washout period, then 12 weeks of active VNS.
Figure 1: Chronogram of the ESNV-SPA study illustrating the screening, randomization, and cross-over treatment periods.

Data Collection and Clinical Endpoints

The study aims to recruit 120 adult patients who have failed at least two biological therapies. Data collection is rigorous, spanning clinical, biological, and quality-of-life metrics across multiple visits.

Figure 2: Schedule of actions and assessments throughout the different phases of the ESNV-SPA study.

The primary endpoint is the ASAS20 response at 12 weeks. This composite measure requires at least a 20% improvement (and an absolute improvement of at least 10 units on a 0–100 scale) in three of the following four domains: patient global assessment, total back pain, function (BASFI), and inflammation (BASDAI morning stiffness). Secondary endpoints include changes in C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and specific cytokine levels (IL-6, TNFα).

Discussion and Future Outlook

The ESNV-SPA study represents a significant step in moving VNS from an invasive surgical procedure to a portable, non-invasive therapy. By targeting the cymba conchae, the protocol leverages precise neuroanatomy to trigger systemic anti-inflammatory effects.

However, the protocol faces challenges, such as potential blinding issues if patients perceive different sensations between the earlobe and the cymba conchae. Additionally, the once-weekly stimulation frequency is relatively conservative. If successful, this trial will provide a foundation for optimizing nVNS dosing and potentially integrating bioelectronic medicine into the standard care for refractory inflammatory diseases.

Trial Registration: ClinicalTrials.gov (NCT04286373).

Summary updated

Abstract

Axial spondyloarthritis (SpA), is a major cause of chronic pain and disability that profoundly alters the quality of life of patients. Nearly half of patients with SpA usually develop drug resistance. Non-pharmacological treatments targeting inflammation are an attractive alternative to drug administration. Vagus nerve stimulation (VNS), by promoting a cholinergic anti-inflammatory reflex holds promise for treating inflammatory disease. Inflammatory reflex signaling, which is enhanced by electrically stimulating the vagus nerve, significantly reduces cytokine production and attenuates disease severity in animal models of endotoxemia, sepsis, colitis, and other preclinical models of inflammatory diseases. It has been proposed that vagal efferent fibers release acetylcholine (Ach), which can interact with α7-subunit-containing nicotinic receptors expressed by tissue macrophages and other immune cells to rapidly inhibit the synthesis/release of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6, and IL-18. External vagal nerve stimulation devices are now available that do not require surgery nor implantation to non-invasively stimulate the vagal nerve. This double-blind randomized cross-over clinical trial aims to study the change in SpA disease activity, according to Assessment in Ankylosing Spondylitis 20 (ASAS20) definition, after 12 weeks of non-invasive VNS treatment vs. non-specific dummy stimulation (control group). One hundred and twenty adult patients with drug resistant SpA, meeting the ASAS classification criteria, will be included in the study. Patients will be randomized into two parallel groups according to a cross over design: either active VNS for 12 weeks, then dummy stimulation for 12 weeks, or dummy stimulation for 12 weeks, then active VNS for 12 weeks. The two stimulation periods will be separated by a 4 weeks wash-out period. A transcutaneous auricular vagus nerve stimulator Tens Eco Plus SCHWA MEDICO<sup>TM</sup> France will be used in this study. The active VNS stimulation will be applied in the cymba conchae of the left ear upon the auricular branch of the vagus nerve, using low intensity (2-5 mA), once à week, during 1 h. Dummy stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at an irrelevant anatomical site: the left ear lobule. This multicenter study was registered on ClinicalTrials.gov: NCT04286373.
BibTeX
@inproceedings{azabou2021randomized,
  author = {Éric Azabou and Guillaume Bao and Félicie Costantino and Madalina Jacota and Chanez Lazizi and Lionelle Nkam and Martin Rottman and Anne‐Laure Roux and Sylvain Chevallier and Lamiae Grimaldi and Maxime Bréban},
  title = {{Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies: The ESNV-SPA Study Protocol}},
  booktitle = {Frontiers in Human Neuroscience},
  year = {2021},
  doi = {10.3389/fnhum.2021.679775},
}
Figure